A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

Journal of the American College of Cardiology

Volumn 35, Issue 1, 2000, Pages 176-182

  Hoeper, Marius M ^a,b   Olschewski, Horst ^a   Ghofrani, Hossein A ^b   Wilkens, Heinrike ^a,c   Winkler, Joerg ^d   Borst, Mathias M ^d   Niedermeyer, Jost ^a   Fabel, Helmut ^e   Seeger, Werner ^a  

^a Hannover Medical School ^*

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; NITRIC OXIDE;

ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS; CLINICAL ARTICLE; DRUG EFFECT; DRUG POTENCY; HEART CATHETERIZATION; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VENOUS OXYGEN TENSION;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; NITRIC OXIDE; OXYGEN; PULMONARY WEDGE PRESSURE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0033977505     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00494-5     Document Type: Article

References (27)

1. Higenbottam TW, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7.
2. Rubin LJ, Mendoza J, Hood M, et al. Treatment of pulmonary hypertension with infusion of prostacyclin (epoprostenol). Ann Intern Med 1990;112:485-91.
3. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
4. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
5. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
6. Hinderliter AL, Willis PW, Barst RJ, et al. Effect of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.
7. McLaughlin W, Genthner D, Panella M, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:272-7.
8. Jolliet P, Bulpa P, Thorens JB, Ritz M, Chevrolet JC. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997;52:369-72.
9. Pepke-Zaba J, Higenbottam TW, Dinh XA, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991;338:1173-4.
10. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-9.
11. Snell GI, Salamonsen RF, Bergin P, et al. Inhaled nitric oxide as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am J Respir Crit Care Med 1995;151: 1263-6.
12. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998;32:1068-73.
13. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93: 484-8.
14. Frostell CG, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasodilation. Circulation 1991;83:2038-47; erratum in Circulation 1991;84:2212.
15. Miller OI. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995;346:51-2.
16. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4.
17. Sinzinger H. Prostacyclin and Its Stable Analogue Iloprost. Gryglewski RS, Stock G, editor. Berlin: Springer, 1987:293-4.
18. Skuballa W, Radüchel B, Vorbrüggen H. Prostacyclin and Its Stable Analogue Iloprost. Gryglewski RS, Stock G, eds. Berlin: Springer, 1987:17-24.
19. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
20. Mohan P, Brutsaert DL, Sys SU. Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins. Cardiovasc Res 1995;29:637-40.
21. Rebsamen MC, Church DJ, Morabito D, Vallotton MB, Lang U. Role of cAMP and calcium influx in endothelin-1-induced ANP release in rat cardiomyocytes. Am J Physiol 1997;273:E922-31.
22. Voelkel NF, Lobel K, Westcott JY, Burke TJ. Nitric oxide-related vasoconstriction in lungs perfused with red cell lysate. FASEB J 1995;5:379-86.
23. Warren JB, Higenbottam TW. Caution with the use of inhaled nitric oxide. Lancet 1996;348:629-30.
24. Olschewski H, Ghofrani HA, Walmrath D, et al. Recovery from circulatory shock in severe primary pulkemonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998;24:631-4.
25. Magnani M, Galie N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 1996;17:18-24.
26. Hoeper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocygotic cell line and in rat lungs via cAMP. Am J Respir Cell Mol Biol 1997;17:748-56.
27. Niewierowicz I, Eskilsson J, Scheja A, Akesson A. Intermittent iloprost infusion therapy for pulmonary hypertension in scleroderma - a pilot study. Scand J Rheumatol 1995;24:123-7.